Jorquera Jorge, Dreyse Jorge, Salas Constanza, Letelier Francisca, Weissglas Bunio, Del-Río Javiera, Henríquez-Beltrán Mario, Labarca Gonzalo, Jorquera-Díaz Jorge
Center for Respiratory Diseases, Las Condes Clinic, Faculty of Medicine, Finis Terrae University, Santiago, Chile.
Department of Clinical Biochemistry and Immunology, Facultad de Farmacia, Universidad de Concepción, Bío-Bío, Chile.
Sleep Sci. 2023 Nov 22;16(4):e446-e453. doi: 10.1055/s-0043-1776770. eCollection 2023 Dec.
To evaluate the clinical utility of the Baveno classification in predicting incident cardiovascular mortality after five years of follow-up in a clinic-based cohort of patients with obstructive sleep apnea (OSA). We evaluated the reproducibility of the Baveno classification using data from the Santiago Obstructive Sleep Apnea (SantOSA) study. The groups were labeled Baveno A (minor symptoms and comorbidities), B (severe symptoms and minor comorbidities), C (minor symptoms and severe comorbidities), and D (severe symptoms and comorbidities). Within-group comparisons were performed using analysis of variance (ANOVA) and post hoc tests. The associations between groups and incident cardiovascular mortality were determined through the Mantel-Cox and Cox proportional hazard ratios (HRs) adjusted by covariables. A total of 1,300 OSA patients were included (Baveno A: 27.7%; B: 28%; C: 16.8%; and D: 27.5%). The follow-up was of 5.4 years. Compared to Baveno A, the fully-adjusted risk of cardiovascular mortality with Baveno B presented an HR of 1.38 (95% confidence interval [95%CI]: 0.14-13.5; = 0.78); with Baveno C, it was of 1.71 (95%CI: 0.18-16.2; = 0.63); and, with Baveno D, of 1.04 (95%CI: 0.12-9.2; = 0.98). We found no interactions involving Baveno group, sex and OSA severity. Among OSA patients, the Baveno classification can describe different subgroups. However, its utility in identifying incident cardiovascular mortality is unclear. Long-term follow-up studies and the inclusion of demographic variables in the classification could improve its ability to detect a high-risk phenotype associated with cardiovascular mortality. The Baveno classification serves as a valuable method for categorizing varying groups of patients afflicted with OSA. Nevertheless, its precision in identifying occurrence of cardiovascular mortality is still unclear.
为评估巴韦诺分类法在以诊所为基础的阻塞性睡眠呼吸暂停（OSA）患者队列中预测五年随访后心血管疾病死亡发生率的临床效用。我们使用圣地亚哥阻塞性睡眠呼吸暂停（SantOSA）研究的数据评估了巴韦诺分类法的可重复性。这些组被标记为巴韦诺A（轻微症状和合并症）、B（严重症状和轻微合并症）、C（轻微症状和严重合并症）和D（严重症状和合并症）。组内比较采用方差分析（ANOVA）和事后检验。通过Mantel-Cox检验以及经协变量调整的Cox比例风险比（HR）来确定组与心血管疾病死亡发生率之间的关联。共纳入1300例OSA患者（巴韦诺A：27.7%；B：28%；C：16.8%；D：27.5%）。随访时间为5.4年。与巴韦诺A相比，巴韦诺B经完全调整后的心血管疾病死亡风险的HR为1.38（95%置信区间[95%CI]：0.14 - 13.5；P = 0.78）；巴韦诺C为1.71（95%CI：0.18 - 16.2；P = 0.
